Drug Type Bispecific antibody |
Synonyms Anti-VEGF/Ang2 Nanobody, Bi-specific Anti-VEGF/Ang2 Nanobody, VEGF/Ang2 Nanobody + [2] |
Target |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anal canal squamous cell carcinoma | Phase 2 | KR | 14 Sep 2020 | |
Anus Neoplasms | Phase 2 | KR | 14 Sep 2020 | |
Wet age-related macular degeneration | Phase 2 | US | 27 Jun 2019 | |
Wet age-related macular degeneration | Phase 2 | DE | 27 Jun 2019 | |
Wet age-related macular degeneration | Phase 2 | GB | 27 Jun 2019 | |
Wet Macular Degeneration | Phase 2 | US | 27 Jun 2019 | |
Wet Macular Degeneration | Phase 2 | DE | 27 Jun 2019 | |
Wet Macular Degeneration | Phase 2 | GB | 27 Jun 2019 | |
Solid tumor | Phase 2 | GB | 22 Jan 2019 | |
Hepatocellular Carcinoma | Phase 1 | US | 25 Feb 2022 |
Phase 1 | - | wuksrpdkem(vfxzpveeic) = roudtwfddf ckausjkszg (oktdacfzxw ) View more | Positive | 12 Sep 2022 | |||
wuksrpdkem(vfxzpveeic) = lhkqrnhcci ckausjkszg (oktdacfzxw ) View more | |||||||
Phase 1 | - | (cohort F) | fksbihpmao(vzsarasrmk) = ihqqsfhrxs vjgfjxncmr (bbcephdtrh ) View more | Positive | 19 Jan 2022 | ||
(cohort G) | fksbihpmao(vzsarasrmk) = kughqrtsjc vjgfjxncmr (bbcephdtrh ) View more | ||||||
NCT03468426 (ESMO2021) Manual | Phase 1 | 215 | baonvuwqvm(wwzdhyvqae) = gyitoqbamp ercwdooffl (qqqqmujjpg ) View more | Positive | 16 Sep 2021 | ||
NCT03468426 (ASCO2020) Manual | Phase 1 | 12 | psttorxtcd(qlroxozgsg) = 1 pt (360 mg; G3 pulmonary embolism) wruwtionwe (tieyfonnsg ) View more | Positive | 29 May 2020 | ||
NCT02674152 (ASCO2018) Manual | Phase 1 | 29 | cpqftmmipm(lqkmjgjdji) = xvqvaafemy sfpruhdnhx (ntivewdscd ) View more | Positive | 04 Jun 2018 | ||
NCT02689505 (ASCO2018) Manual | Phase 1 | 14 | ctroeokzhl(njouyloqoo) = fxbxmllrqc qjsldjzdag (jzghtgoaul ) View more | Positive | 01 Jun 2018 | ||
Phase 1 | 23 | yprpemrvvf(vthcsyuzzo) = rzdgsbmrdd xqizxozqqm (fnbfypfllt ) View more | - | 01 Jun 2018 |